Demographic, laboratory, and clinical features of ChAdOx1 nCoV-19 (AstraZeneca)-associated VITT patients
| Patient code . | Age (y) . | Sex . | Timing of symptom onset after vaccination (d) . | Platelets (×109/L)∗ . | Fibrinogen (g/L)§,† . | D-dimer (mg/L)‡ . | Thrombotic features . | Asserachrom HPIA IgG, Stago (OD)§ . | Life codes PF4 IgG, Immucor (OD)‖ . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| VITT 1 | 73 | F | 12 | 11 | 1.1 | 44.7 | CVST with secondary ICH | 2.43 | 3.14 | Died |
| VITT 2 | 59 | F | 15 | 13 | 1.5 | >80 | CVST, PE, SVT | 0.73 | 3.39 | Recovered |
| VITT 3 | 88 | F | 13 | 57 | 1.3 | 52.4 | Bilateral DVT | 2.24 | 0.89 | Recovered |
| VITT 4 | 54 | M | 13 | 60 | 1.0 | >80 | SVT requiring bowel resection | 2.18 | 1.17 | Recovered |
| VITT 5 | 49 | F | 12 | 40 | 1.4 | 35 | CVST, DVT | 1.46 | 1.08 | Recovered |
| Patient code . | Age (y) . | Sex . | Timing of symptom onset after vaccination (d) . | Platelets (×109/L)∗ . | Fibrinogen (g/L)§,† . | D-dimer (mg/L)‡ . | Thrombotic features . | Asserachrom HPIA IgG, Stago (OD)§ . | Life codes PF4 IgG, Immucor (OD)‖ . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| VITT 1 | 73 | F | 12 | 11 | 1.1 | 44.7 | CVST with secondary ICH | 2.43 | 3.14 | Died |
| VITT 2 | 59 | F | 15 | 13 | 1.5 | >80 | CVST, PE, SVT | 0.73 | 3.39 | Recovered |
| VITT 3 | 88 | F | 13 | 57 | 1.3 | 52.4 | Bilateral DVT | 2.24 | 0.89 | Recovered |
| VITT 4 | 54 | M | 13 | 60 | 1.0 | >80 | SVT requiring bowel resection | 2.18 | 1.17 | Recovered |
| VITT 5 | 49 | F | 12 | 40 | 1.4 | 35 | CVST, DVT | 1.46 | 1.08 | Recovered |
CVST, cerebral venous sinus thrombosis; DVT, deep vein thrombosis of legs; ELISA, enzyme-linked immunosorbent assay; F, female; ICH, intracerebral hemorrhage; M, male; OD, optical density; PE, pulmonary embolism; SVT, splanchnic vein thrombosis.
Reference range: 150 to 450 × 109/L.
Reference range: 1.5 to 4.0 g/L.
Cutoff value: <0.5 mg/L.
ELISA cutoff value: OD ≤ 0.21.
ELISA cutoff value: OD < 0.4.